STOCK TITAN

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MindMed (NASDAQ: MNMD) reported Q3 2024 financial results and provided updates on its clinical programs. The company is preparing to launch three Phase 3 studies, including the Voyage study for GAD in Q4 2024, with topline data expected in H1 2026. Cash position stands at $295.3 million, expected to fund operations into 2027. Q3 2024 saw R&D expenses of $17.2 million and net loss of $13.7 million. The company's MM120 ODT program is advancing with additional Phase 3 studies Panorama (GAD) and Emerge (MDD) planned for H1 2025, targeting conditions affecting approximately 51 million U.S. adults.

MindMed (NASDAQ: MNMD) ha riportato i risultati finanziari del terzo trimestre del 2024 e fornito aggiornamenti sui suoi programmi clinici. L'azienda si sta preparando a lanciare tre studi di Fase 3, inclusa lo studio Voyage per il GAD nel quarto trimestre del 2024, con i dati preliminari attesi nella prima metà del 2026. La posizione di cassa è di 295,3 milioni di dollari, prevista per finanziare le operazioni fino al 2027. Nel terzo trimestre del 2024, le spese per R&S sono state di 17,2 milioni di dollari e la perdita netta di 13,7 milioni di dollari. Il programma MM120 ODT dell'azienda sta avanzando con ulteriori studi di Fase 3, Panorama (GAD) ed Emerge (MDD) pianificati per la prima metà del 2025, mirando a condizioni che colpiscono circa 51 milioni di adulti negli Stati Uniti.

MindMed (NASDAQ: MNMD) informó los resultados financieros del tercer trimestre de 2024 y proporcionó actualizaciones sobre sus programas clínicos. La empresa se está preparando para lanzar tres estudios de Fase 3, incluido el estudio Voyage para el GAD en el cuarto trimestre de 2024, con datos preliminares esperados para la primera mitad de 2026. La posición de efectivo asciende a 295.3 millones de dólares, esperando financiar operaciones hasta 2027. En el tercer trimestre de 2024, los gastos de I+D fueron de 17.2 millones de dólares y la pérdida neta fue de 13.7 millones de dólares. El programa MM120 ODT de la empresa avanza con estudios adicionales de Fase 3, Panorama (GAD) y Emerge (MDD) planeados para la primera mitad de 2025, dirigidos a condiciones que afectan a aproximadamente 51 millones de adultos en EE. UU.

MindMed (NASDAQ: MNMD)는 2024년 3분기 재무 결과를 보고하고 임상 프로그램에 대한 업데이트를 제공했습니다. 이 회사는 2024년 4분기에 GAD를 위한 Voyage 연구를 포함한 3개의 3상 연구를 출시할 준비를 하고 있으며, 주요 데이터는 2026년 상반기에 예상됩니다. 현금 보유고는 2억 9,530만 달러로, 2027년까지 운영 자금을 지원할 것으로 예상됩니다. 2024년 3분기 R&D 비용은 1,720만 달러였고, 순손실은 1,370만 달러였습니다. 회사의 MM120 ODT 프로그램은 2025년 상반기를 목표로 하는 추가 3상 연구인 Panorama (GAD) 및 Emerge (MDD)와 함께 진전되고 있으며, 이는 약 5,100만 명의 미국 성인에게 영향을 미치는 질환을 목표로 하고 있습니다.

MindMed (NASDAQ: MNMD) a rapporté les résultats financiers du troisième trimestre 2024 et a fourni des mises à jour sur ses programmes cliniques. L'entreprise se prépare à lancer trois études de Phase 3, y compris l'étude Voyage pour le GAD au quatrième trimestre 2024, avec des données préliminaires attendues au premier semestre 2026. La position de trésorerie s'élève à 295,3 millions de dollars, prévue pour financer les opérations jusqu'en 2027. Au troisième trimestre 2024, les dépenses de R&D étaient de 17,2 millions de dollars et la perte nette de 13,7 millions de dollars. Le programme MM120 ODT de l'entreprise avance avec d'autres études de Phase 3, Panorama (GAD) et Emerge (MDD) prévues pour le premier semestre 2025, visant des conditions touchant environ 51 millions d'adultes aux États-Unis.

MindMed (NASDAQ: MNMD) hat die Finanzzahlen für das 3. Quartal 2024 veröffentlicht und Updates zu seinen klinischen Programmen bereitgestellt. Das Unternehmen bereitet sich darauf vor, drei Phase-3-Studien zu starten, einschließlich der Voyage-Studie für GAD im 4. Quartal 2024, mit Ergebnissen, die für das 1. Halbjahr 2026 erwartet werden. Die Liquiditätsposition beläuft sich auf 295,3 Millionen Dollar, die voraussichtlich die Geschäftstätigkeit bis 2027 finanzieren werden. Im 3. Quartal 2024 lagen die F&E-Ausgaben bei 17,2 Millionen Dollar und der Nettverlust bei 13,7 Millionen Dollar. Das MM120 ODT-Programm des Unternehmens schreitet voran, mit weiteren Phase-3-Studien, Panorama (GAD) und Emerge (MDD), die für das 1. Halbjahr 2025 geplant sind und Bedingungen ansprechen, die etwa 51 Millionen Erwachsene in den USA betreffen.

Positive
  • Strong cash position of $295.3 million, sufficient to fund operations into 2027
  • Net loss decreased by $4.2 million to $13.7 million compared to Q3 2023
  • G&A expenses decreased by $0.8 million compared to Q3 2023
Negative
  • R&D expenses increased by $4.0 million compared to Q3 2023
  • Net cash used in operating activities increased to $53.8 million from $43.8 million YoY

Insights

The Q3 results show a robust financial position with $295.3 million in cash, a significant increase from $99.7 million at year-end 2023. This runway extends into 2027, well beyond the first Phase 3 readout. R&D expenses increased by $4.0 million to $17.2 million, reflecting investment in clinical programs. The net loss decreased by $4.2 million to $13.7 million, primarily due to warrant valuation changes. The company's cash position appears strong enough to support three planned Phase 3 trials targeting a substantial market of 51 million U.S. adults.

The advancement to Phase 3 trials represents a significant milestone in psychedelic medicine development. The comprehensive trial design includes adaptive sample sizing and clear endpoints using established scales (HAM-A for anxiety and MADRS for depression). The multi-pronged approach targeting both GAD and MDD with MM120 ODT shows strategic diversification. The completion of MM402's Phase 1 study for ASD also demonstrates pipeline progression. The planned trials' structure, with 12-week double-blind periods followed by 40-week extensions, provides robust data collection opportunities for safety and efficacy assessment.

--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026--

--On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025--

--Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--

--Company to host a conference call today at 4:30 p.m. EST--

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update.

“This is a pivotal moment for MindMed as we prepare to initiate Voyage, our first Phase 3 study of MM120 ODT in GAD,” said Rob Barrow, Chief Executive Officer of MindMed. “Beyond Voyage, we are on track to initiate two additional Phase 3 studies: the Panorama study, our second trial in GAD, and the Emerge study, our first trial of MM120 ODT in MDD. Our Phase 3 development strategy leverages high-performing clinical trial sites from our Phase 2 study, as well as thoughtfully aligned protocols, which we expect to enable efficient enrollment across GAD and MDD. Our strong execution throughout the year has positioned us as a well-financed, late-stage clinical leader, set to launch three Phase 3 studies targeting two indications affecting approximately 51 million adults in the U.S. I could not be more pleased with our progress as we continue to build a high-performing organization dedicated to transforming the standard of care for people with brain health disorders.”

Program Updates and Anticipated Milestones

MM120 (lysergide D-tartrate) for GAD

  • The Company is on track to initiate the Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of adults with GAD in the fourth quarter of 2024. The Company expects the topline readout from the 12-week double-blind period (Part A) of Voyage in the first half of 2026.
  • The Phase 3 clinical program for MM120 ODT in GAD consists of two clinical studies: the Voyage study (MM120-300) and the Panorama study (MM120-301).
    • Both studies are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel group study assessing the efficacy and safety of MM120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT, subject to certain conditions for treatment eligibility.
    • Voyage is anticipated to enroll approximately 200 participants in the U.S. who will be randomized 1:1 to receive MM120 ODT 100 µg or placebo, and Panorama is anticipated to enroll approximately 240 participants (randomized 5:2:5 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo).
    • The primary endpoint for each study is the change from baseline in Hamilton Anxiety Rating Scale (HAM-A) score at Week 12 between MM120 ODT 100 µg and placebo.
    • Both studies are expected to employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. participant retention rate, variability of primary outcome measure) which allows for an increase of sample size up to 50% to maintain statistical power.
  • Panorama, the second Phase 3 study, will be conducted in the U.S. and Europe and is on track to initiate in the first half of 2025 with an anticipated topline readout from the 12-week double-blind period (Part A) in the second half of 2026.

MM120 (lysergide D-tartrate) for MDD

  • The Company is also developing MM120 ODT for the treatment of adults with MDD, beginning with the Emerge study (MM120-310) which, like the Phase 3 studies in GAD, is comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of MM120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT, subject to certain conditions for treatment eligibility.
    • Emerge is anticipated to enroll at least 140 participants (randomized 1:1 to receive MM120 ODT 100 µg or placebo).
    • The primary endpoint is the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between MM120 ODT 100 µg and placebo.
    • The Company expects to initiate Emerge in the first half of 2025 with an anticipated topline readout from the 12-week double-blinded period (Part A) in the second half of 2026.
    • The Company expects to conduct a second Phase 3 registrational study in MDD, with the study design and timing to be informed by the progress of Emerge and additional regulatory discussion.

MM402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD)

  • In October, the Company completed a Phase 1 study of MM402, a single-ascending dose study in adult healthy volunteers. The study was intended to characterize the tolerability, pharmacokinetics and pharmacodynamics of MM402. The Company expects to initiate further studies of MM402 for the potential treatment of ASD, with the exact timing and scope of such studies to be determined.

Third Quarter 2024 Financial Results

Cash Balance. As of September 30, 2024, MindMed had cash and cash equivalents totaling $295.3 million compared to $99.7 million as of December 31, 2023.

The Company believes that its cash and cash equivalents as of September 30, 2024, will be sufficient to fund the Company’s operations into 2027. Based on the Company’s current operating plan and anticipated R&D milestones, the Company expects its cash runway to extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD.

Net Cash Used in Operating Activities. For the nine months ended September 30, 2024, net cash used in operating activities was $53.8 million, compared to $43.8 million in the nine months ended September 30, 2023.

Research and Development (R&D). R&D expenses were $17.2 million for the quarter ended September 30, 2024, compared to $13.2 million for the quarter ended September 30, 2023, an increase of $4.0 million. The increase was primarily due to $2.1 million in expenses related to our MM120 program supporting the advancement into pivotal studies for the treatment of adults with GAD, $0.9 million in expenses related to our MM402 program, $0.6 million in internal personnel costs as a result of increasing research and development capacities, and an increase of $0.4 million in expenses related to preclinical activities.

General and Administrative (G&A). G&A expenses were $7.6 million for the quarter ended September 30, 2024, compared to $8.4 million for the quarter ended September 30, 2023, a decrease of $0.8 million. The decrease was primarily attributable to lower spending in legal and commercial activities, partially offset by an increase in stock-based compensation expense.

Net Loss. Net loss for the quarter ended September 30, 2024, was $13.7 million, compared to $17.9 million for the same period in 2023, a decrease of $4.2 million. The decrease was primarily due to changes in the fair value of warrants issued in our September 2022 underwritten offering of $5.3 million partially offset by an increase in research and development expense.

Conference Call and Webcast Reminder

MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s third quarter 2024 financial results. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MM120

MM120 (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors. MindMed is developing MM120, the tartrate salt form of lysergide, for GAD and MDD and is exploring its potential applications in other serious brain health disorders. Based on the significant unmet medical need in the treatment of GAD – especially in patients who do not respond to or tolerate currently available medications – along with the initial clinical data from Phase 2b and other research conducted by MindMed, the U.S. Food & Drug Administration (FDA) has designated MM120 for GAD as a breakthrough therapy. The MM120 ODT Phase 3 clinical development program includes the Voyage and Panaroma studies in GAD and the Emerge study in MDD. Additional clinical indications under consideration.

About MM402

MM402 is the Company’s proprietary form of R(-)-MDMA (rectus-3,4-methylenedioxymethamphetamine), being developed for the treatment of core symptoms of ASD. MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company’s expectation to initiate the Phase 3 Voyage study of MM120 ODT in GAD in the fourth quarter of 2024 with an anticipated topline readout (Part A results) in the first half of 2026; the Company’s expectation to initiate the Phase 3 Panorama study for MM120 ODT in GAD in the first half of 2025 with an anticipated topline readout (Part A results) in the second half of 2026; the Company’s expectation to initiate the Phase 3 Emerge study for MM120 ODT in MDD in the first half of 2025 with an anticipated topline readout (Part A results) in the second half of 2026; the Company’s plans to conduct a second Phase 3 study in MDD; the Company’s expectations regarding the enrollment for each of the Voyage, Panorama and Emerge studies; the Company’s beliefs regarding potential benefits of its product candidates; the Company’s expectation to conduct further studies of MM402; the Company’s expectation that its cash and cash equivalents will fund operations into 2027; the Company’s expectation that its cash runway will extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD; the Company’s anticipated upcoming milestones, trials and studies; and potential additional indications for MM120 and MM402. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

Mind Medicine (MindMed) Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

$

17,188

 

 

$

13,203

 

 

$

43,538

 

 

$

40,578

 

General and administrative

 

 

7,604

 

 

 

8,413

 

 

 

27,916

 

 

 

31,083

 

Total operating expenses

 

 

24,792

 

 

 

21,616

 

 

 

71,454

 

 

 

71,661

 

Loss from operations

 

 

(24,792

)

 

 

(21,616

)

 

 

(71,454

)

 

 

(71,661

)

Other income/(expense):

 

 

 

 

 

 

 

 

Interest income

 

 

3,507

 

 

 

1,491

 

 

 

8,279

 

 

 

4,240

 

Interest expense

 

 

(727

)

 

 

(328

)

 

 

(1,627

)

 

 

(481

)

Foreign exchange loss, net

 

 

(32

)

 

 

(439

)

 

 

(589

)

 

 

(244

)

Change in fair value of 2022 USD Financing Warrants

 

 

8,360

 

 

 

3,020

 

 

 

(11,088

)

 

 

(3,671

)

Gain on extinguishment of contribution payable

 

 

 

 

 

 

 

 

2,541

 

 

 

 

Other expense

 

 

 

 

 

(51

)

 

 

 

 

 

(51

)

Total other income/(expense), net

 

 

11,108

 

 

 

3,693

 

 

 

(2,484

)

 

 

(207

)

Net loss

 

 

(13,684

)

 

 

(17,923

)

 

 

(73,938

)

 

 

(71,868

)

Other comprehensive loss

 

 

 

 

 

 

 

 

Gain/(loss) on foreign currency translation

 

 

(12

)

 

 

415

 

 

 

478

 

 

 

150

 

Comprehensive loss

 

$

(13,696

)

 

$

(17,508

)

 

$

(73,460

)

 

$

(71,718

)

Net loss per common share, basic

 

$

(0.18

)

 

$

(0.45

)

 

$

(1.12

)

 

$

(1.85

)

Net loss per common share, diluted

 

$

(0.27

)

 

$

(0.45

)

 

$

(1.12

)

 

$

(1.85

)

Weighted-average common shares, basic

 

 

77,909,441

 

 

 

39,720,007

 

 

 

65,938,025

 

 

 

38,798,374

 

Weighted-average common shares, diluted

 

 

80,238,688

 

 

 

39,720,007

 

 

 

65,938,025

 

 

 

38,798,374

 

Mind Medicine (MindMed) Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

 

 

 

September 30,

2024 (Unaudited)

 

 

December 31,

2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

295,284

 

 

$

99,704

 

Prepaid and other current assets

 

 

4,074

 

 

 

4,168

 

Total current assets

 

 

299,358

 

 

 

103,872

 

Goodwill

 

 

19,918

 

 

 

19,918

 

Intangible assets, net

 

 

 

 

 

527

 

Other non-current assets

 

 

493

 

 

 

224

 

Total assets

 

$

319,769

 

 

$

124,541

 

 

 

 

 

 

 

 

Liabilities and Shareholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,149

 

 

$

4,136

 

Accrued expenses

 

 

8,796

 

 

 

11,634

 

2022 USD Financing Warrants

 

 

22,320

 

 

 

16,476

 

Total current liabilities

 

 

33,265

 

 

 

32,246

 

Credit facility, long-term

 

 

24,311

 

 

 

14,129

 

Other liabilities, long-term

 

 

 

 

 

32

 

Total liabilities

 

 

57,576

 

 

 

46,407

 

 

 

 

 

 

 

 

Shareholders' Equity:

 

 

 

 

 

 

Common shares, no par value, unlimited authorized as of September 30, 2024 and December 31, 2023; 81,590,491 and 41,101,303 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

 

 

 

 

 

 

Additional paid-in capital

 

 

625,510

 

 

 

367,991

 

Accumulated other comprehensive income

 

 

821

 

 

 

343

 

Accumulated deficit

 

 

(364,138

)

 

 

(290,200

)

Total shareholders' equity

 

 

262,193

 

 

 

78,134

 

Total liabilities and shareholders' equity

 

$

319,769

 

 

$

124,541

 

 

For Media: media@mindmed.co

For Investors: ir@mindmed.co

Source: Mind Medicine Inc.

FAQ

What is MindMed's (MNMD) cash position as of Q3 2024?

MindMed reported cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027.

When will MindMed (MNMD) initiate the Phase 3 Voyage study for GAD?

MindMed plans to initiate the Phase 3 Voyage study for GAD in the fourth quarter of 2024, with topline data expected in the first half of 2026.

What was MindMed's (MNMD) net loss in Q3 2024?

MindMed reported a net loss of $13.7 million for Q3 2024, a decrease of $4.2 million compared to the same period in 2023.

Mind Medicine (MindMed) Inc. Common Shares

NASDAQ:MNMD

MNMD Rankings

MNMD Latest News

MNMD Stock Data

555.12M
72.48M
1.14%
68.1%
13.61%
Biotechnology
Medicinal Chemicals & Botanical Products
Link
United States of America
NEW YORK